messag updat estim follow
result remov price target increas price target
remov price target revenu
estim move
increas pt price-to-earnings target multipl
revenu estim
base primarili recent
court decis allow extens tecfidera ip
increas pt price-to-earnings target multipl
revenu estim move
respect given
final restructur agreement sanofi san-par buy
look addit clariti restructur agreement
page analyst certif import disclosur
valuat risk
remov pt
project ep compound-annual-growth-rate think l-t sustain franchis light
competit remain concern therefor think share unlik trade premium peer
maintain neutral rate see major catalyst near intermedi term
weak metabol sale patient transit soliris-to-ultomiri result lower revenu per patient
downsid risk includ failur secur approv ultomiri addit indic slower
expect soliri growth mg upsid risk includ substanti larger expect growth soliri sale
neurolog franchis larg growth pnh/ahu popul treatment
page analyst certif import disclosur
compani report guggenheim secur llc estim
page analyst certif import disclosur
inc yatin suneja complement qoq total yoy yoy metabol franchis qoq yoy total revenu qoq gross oper oper oper incom non-gaap tax incom loss net incom net gaap qoq yoy ep exclud stock-comp item debt net mm except per share unit
valuat risk
increas pt base rais price-to-earnings target multipl
rais multipl valu line greater peer group biotech compani
believ accur reflect resili eylea franchis continu robust perform
dupix strong io pipelin compani recent describ
pt vs previous base vs prior non-gaap ep estim
support risk-adjust npv vs prior
downsid risk includ failur secur approv eylea/dupixent/libtayo addit indic rapid
complet implement -like seri regul
page analyst certif import disclosur
compani report guggenheim secur llc estim
page analyst certif import disclosur
yatin suneja chang chang product collabor global sale record global sale record global sale record ex-u sale cemiplimab record reimburs includ commerci share antibodi commerci share io commerci collabor eylea row chang chang eylea reimbursements/amort eylea row profit ou licens includ teva research chang chang collabor zaltrap row eylea non- reimburs non- reimburs teva non- unreimburs stock-bas non- commerci expens reimburst sni sg expens reimburst sg expens non- core stock-bas rate incom net net incom chang chang basic dilut cash per debt per sharecash flow gener mm except pre share unit
valuat risk
pt previous base previous ep estim rais pt
target multipl line peer group averag account recent court decis
allow extens tecfidera ip continu potenti aducanumab also
support risk-adjust npv
downsid risk includ failur alzheim asset pipelin setback well faster
expect shrinkag older portion ms portfolio avonex plegridi etc
page analyst certif import disclosur
compani report guggenheim secur llc estim
page analyst certif import disclosur
interferon ms alzheimar yoy product rituxan/gazyva sale right incom interest net incom ep stock tax net incom includ non-cash stock ep includ stock share outstand ep exclud stock-comp item mm except per share unitsyatin suneja
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst whose name appear report receiv compens base upon variou factor includ qualiti research
investor client feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc affili expect receiv intend seek compens invest bank servic alexion
pharmaceut inc inc biogen inc next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
rate price target histori inc
creat bluematrix
rate price target histori inc
creat bluematrix
page analyst certif import disclosur
